INTRODUCTION Progressive macular hypomelanosis (PMH) is a common but under-recognized disorder characterized by multiple non-scaly, nummular hypopigmented macules and patches distributed symmetrically on the trunk and proximal extremities of young…
Read More
INTRODUCTION Vitiligo vulgaris affects 0.4-1 percent of the world population. 1 Pockets of areas of high incidence (as high as 8%) have been reported in India.2 While vitiligo vulgaris affects…
Read More
INTRODUCTION Scalp hyperkeratosis, with or without alopecia, is a common clinical finding seen in pediatric dermatology practices, especially those with children of color. In such cases, fungal cultures are routinely…
Read More
INTRODUCTION Melasma is an acquired skin condition characterized by irregular brown or hyperpigmented patches typically located on the forehead, cheeks, nose, chin and upper lip.1 It is more commonly seen…
Read More
INTRODUCTIONCensus predictions project that persons with skin of color will constitute approximately 50 percent of the United States (US) population by the year 2050.1 As such, particular attention to skin…
Read More
INTRODUCTION Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder which affects 10 to 20 percent of the general population.1-3 Symptoms of AD include dry, scaly and intensely itchy…
Read More
INTRODUCTION Psoriasis is a chronic, genetic, immune-mediated, inflammatory skin disorder affecting approximately two percent of the Caucasian population.1 Tumor necrosis factor-α (TNF-α) has been postulated to be a key regulator…
Read More
CASE REPORT A 54 year old female was evaluated for wound breakdown after breast reconstruction with pedicle transverse rectus abdominal myocutaneous (TRAM) flap. Two years prior to this, the patient…
Read More
What's New in Treatment of Keloids? New Applications for Common Therapies, New Treatments to Come.Keloids have long been a distressing complication of wound healing. While keloids can be treated by…
Read More
FDA Approval of Ipilimumab The FDA has approved Yervoy (ipilimumab) to treat patients with late-stage (metastatic) melanoma after a successful study showed increased survival time. The study enrolled 676 patients…
Read More
On behalf of the Editors, and also the support staff of the Journal of Drugs in Dermatology, I want to invite all of you to dig into what is a…
Read More
The Journal of Drugs in Dermatology(JDD) and the field of dermatology are now more international than ever before. This is due to both the popularization of international conferences, congresses and…
Read More
